汉森制药(002412) - 2017 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2017 was ¥198,637,113.99, representing an increase of 8.59% compared to ¥182,917,132.27 in the same period last year[8]. - The net profit attributable to shareholders for Q1 2017 was ¥29,536,060.34, up 3.86% from ¥28,437,521.33 year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥28,926,152.12, reflecting a 12.37% increase from ¥25,742,996.47 in the previous year[8]. - The basic earnings per share for Q1 2017 was ¥0.0998, an increase of 3.85% from ¥0.0961 in the same period last year[8]. - The diluted earnings per share for Q1 2017 was also ¥0.0998, reflecting a 3.85% increase compared to ¥0.0961 year-on-year[8]. - The weighted average return on equity was 2.32%, slightly up from 2.31% in the previous year[8]. - The company expects net profit attributable to shareholders for the first half of 2017 to range from 45.56 million yuan to 60.75 million yuan, representing a change of -10.00% to 20.00% compared to the same period in 2016[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥14,296,361.17, a decline of 131.45% compared to ¥45,454,823.62 in the same period last year[8]. - Cash and cash equivalents decreased by 51.15 million yuan, a decline of 42.48%, primarily due to tax payments of 32.45 million yuan and a payment of 28 million yuan for acquiring bankruptcy assets[15]. - The company reported a significant decrease in cash and cash equivalents, down 41.20 million yuan, a decline of 411.95%, primarily due to reduced operating cash flow[17]. - The total assets at the end of the reporting period were ¥1,693,925,692.91, an increase of 1.17% from ¥1,674,388,729.53 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,287,960,621.59, up 2.35% from ¥1,258,424,561.25 at the end of the previous year[8]. Receivables and Prepayments - Accounts receivable increased by 31.98 million yuan, a growth of 43.06%, mainly due to an increase in bank acceptance bills in sales collections[15]. - Prepayments increased by 26.78 million yuan, a growth of 570.38%, primarily due to a payment of 23 million yuan for acquiring bankruptcy assets[15]. - Other receivables decreased by 5.18 million yuan, a decline of 35.38%, mainly due to the recovery of 11.25 million yuan from Hunan Sanxiang Bank[15]. Financial Expenses and Investment Income - Financial expenses increased by 3.08 million yuan, a growth of 2376.42%, mainly due to an increase in bank loans and corresponding interest expenses[16]. - Investment income increased by 1.80 million yuan, primarily due to increased long-term equity investment income from Hunan Sanxiang Bank[16]. Non-Recurring Gains and Losses - The company reported non-recurring gains and losses totaling ¥609,908.22 for the reporting period[9].